» Articles » PMID: 23673977

The Immune System in Stroke: Clinical Challenges and Their Translation to Experimental Research

Overview
Date 2013 May 16
PMID 23673977
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Stroke represents an unresolved challenge for both developed and developing countries and has a huge socio-economic impact. Although considerable effort has been made to limit stroke incidence and improve outcome, strategies aimed at protecting injured neurons in the brain have all failed. This failure is likely to be due to both the incompleteness of modelling the disease and its causes in experimental research, and also the lack of understanding of how systemic mechanisms lead to an acute cerebrovascular event or contribute to outcome. Inflammation has been implicated in all forms of brain injury and it is now clear that immune mechanisms profoundly influence (and are responsible for the development of) risk and causation of stroke, and the outcome following the onset of cerebral ischemia. Until very recently, systemic inflammatory mechanisms, with respect to common comorbidities in stroke, have largely been ignored in experimental studies. The main aim is therefore to understand interactions between the immune system and brain injury in order to develop novel therapeutic approaches. Recent data from clinical and experimental research clearly show that systemic inflammatory diseases -such as atherosclerosis, obesity, diabetes or infection - similar to stress and advanced age, are associated with dysregulated immune responses which can profoundly contribute to cerebrovascular inflammation and injury in the central nervous system. In this review, we summarize recent advances in the field of inflammation and stroke, focusing on the challenges of translation between pre-clinical and clinical studies, and potential anti-inflammatory/immunomodulatory therapeutic approaches.

Citing Articles

Post-stroke fatigue - a multidimensional problem or a cluster of disorders? A case for phenotyping post-stroke fatigue.

Kuppuswamy A J Physiol. 2024; 603(3):759-772.

PMID: 39487999 PMC: 11782906. DOI: 10.1113/JP285900.


Reporting quality in preclinical animal experimental research in 2009 and 2018: A nationwide systematic investigation.

Kousholt B, Praestegaard K, Stone J, Thomsen A, Johansen T, Ritskes-Hoitinga M PLoS One. 2022; 17(11):e0275962.

PMID: 36327216 PMC: 9632797. DOI: 10.1371/journal.pone.0275962.


Consensus clustering of gene expression profiles in peripheral blood of acute ischemic stroke patients.

Yang Z, Wang G, Luo N, Tsang C, Huang L Front Neurol. 2022; 13:937501.

PMID: 35989931 PMC: 9388856. DOI: 10.3389/fneur.2022.937501.


Antibiotic Class and Outcome in Post-stroke Infections: An Individual Participant Data Pooled Analysis of VISTA-Acute.

Smith C, Heal C, Vail A, Jeans A, Westendorp W, Nederkoorn P Front Neurol. 2019; 10:504.

PMID: 31156537 PMC: 6527959. DOI: 10.3389/fneur.2019.00504.


Antibiotic prophylaxis for infections in patients with acute stroke: a systematic review and meta-analysis of randomized controlled trials.

Xi Y, Tian X, Chen W, Zhang S, Zhang S, Ren W Oncotarget. 2017; 8(46):81075-81087.

PMID: 29113368 PMC: 5655263. DOI: 10.18632/oncotarget.19039.


References
1.
Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B . Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity. Circulation. 2004; 109(8):1010-5. DOI: 10.1161/01.CIR.0000117232.30832.EC. View

2.
Emberson J, Bennett D, Link E, Parish S, Danesh J, Armitage J . C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011; 377(9764):469-76. PMC: 3042687. DOI: 10.1016/S0140-6736(10)62174-5. View

3.
Dinapoli V, Benkovic S, Li X, Kelly K, Miller D, Rosen C . Age exaggerates proinflammatory cytokine signaling and truncates signal transducers and activators of transcription 3 signaling following ischemic stroke in the rat. Neuroscience. 2010; 170(2):633-44. PMC: 2933458. DOI: 10.1016/j.neuroscience.2010.07.011. View

4.
Purushothaman K, Krishnan P, Purushothaman M, Wiley J, Alviar C, Ruiz F . Expression of angiotensin-converting enzyme 2 and its end product angiotensin 1-7 is increased in diabetic atheroma: implications for inflammation and neovascularization. Cardiovasc Pathol. 2012; 22(1):42-8. DOI: 10.1016/j.carpath.2012.05.004. View

5.
Pinteaux E, Rothwell N, Boutin H . Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia. 2005; 53(5):551-6. DOI: 10.1002/glia.20308. View